Skip to main content

Table 4 Management of adverse reactions

From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis

Management

No.

% of total reactions

Retreated?

Able to resume/complete infusion

8

28.6%

Y - 1 (2 further cycles with reaction)

Had to cease infusion

7

25.0%

Y - 1 (2 further cycles)

Hospital Admission > 24 h

3

10.7%

Y - 1 (1 further cycle) reaction)

Delayed reaction

5

17.9%

Y - 1 (1 further cycle)

Unclassifieda

4

14.3%

N

Death

1

3.6%

n/a

  1. aDue to lack of clinical data